Listen on the go
CORRECT!
Next question
touchIMMUNOLOGY touchIMMUNOLOGY

Start Learning

Touch Loading image
JOURNALS
Start Learning
Foreword – touchREVIEWS in RMD, Volume 4, Issue 1, 2025
EULAR 2025 BARCELONA HIGHLIGHTS
JOURNALS
Start Learning
Inside EULAR 2025: Breakthroughs and Expert Perspectives in Rheumatology
Screening for Interstitial Lung Disease in Systemic Autoimmune Rheumatic Diseases: Current Evidence and ACR 2023 Guideline Recommendations
JOURNALS
Start Learning
Screening for Interstitial Lung Disease in Systemic Autoimmune Rheumatic Diseases: Muhammad Nisar, BSR 2025
A closeup of inflamed tissue healing over time, with a progression from active inflammation to a healthier state Inflammatory bowel disease IBD concept.
JOURNALS
Start Learning
Study finds comparable cardiovascular risk between JAKi and anti-TNFs in IBD
Mirikizumab, Crohn’s disease
JOURNALS
Start Learning
Mirikizumab maintains efficacy in patients with Crohn’s disease previously treated with ustekinumab: One-year results from VIVID-2
touchEXPERT OPINIONS
Start Learning
Primary biliary cholangitis: Appraising the changing therapeutic landscape
CE/CME ACCREDITED
touchEXPERT BRIEFING
Start Learning
Advances in the treatment of lupus and Sjögren’s disease
Sponsored content
Medics for Rare Disease
JOURNALS
Start Learning
Medics For Rare Disease – New Year, New Strategy
JOURNALS
Start Learning
New study reveals elevated cognitive impairment risk in rheumatoid arthritis patients, linked to inflammation and comorbidities
3d medical x ray of knee pain with arthritis inflammation and tendon injury, copy space
JOURNALS
Start Learning
Clinical Approach to the Care of Patients with Immune Checkpoint Inhibitor-associated Inflammatory Arthritis

to view Favourites, Keep Notes and Track CME Credits

Favourites
RGB-19 Matches Tocilizumab in Efficacy and Safety: Promising Phase III Data from RA Biosimilar Trial
View
Primary biliary cholangitis: Appraising the changing therapeutic landscape
View
Navigating the management of cholestatic pruritus in patients with PBC: Insights from the multidisciplinary team
View
Inside EULAR 2025: Breakthroughs and Expert Perspectives in Rheumatology
View
Advancing Osteoarthritis Research Through Immunology and Clinical Insight: An Interview with Future Leader, Dr Tom Appleton
View
Breakfree-1: Next-Gen CD19 CAR T Shows Promising Immune Reset Potential in Refractory Systemic Sclerosis
View
The STENOVA Trial, a First-in-Class, First-in-Indication Study of AGMB-129 in Fibrostenotic Crohn’s Disease: Florian Rieder, DDW 2025
View
RMDs: What to Expect in 2025
View
Turning your Clinical Expertise into Business Success
View
Medics For Rare Disease – New Year, New Strategy
View
Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
Close Popup